RISK FACTORS FOR THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE DISEASES
Abstract
In this paper, we studied theая prognostic significance rof the rs1801133 polymorphic locus of the MTHFR gene in the developmentof venous thromboembolic complications in patients with Ph-negative MPD.
The results obtained indicate that there is a tendency to form a hypercoagulable syndrome and the risk of thrombosis in patients with MPD with the presence of the unfavorable 677T allele of the MTHFR gene in the genotype. The results of the study indirectly indicate the regulatory "suppressive" effect of allelic variants 677T of the rs1801133 polymorphism of the MTHFR gene on the production of the MTHFR enzyme, leading to hyperhomocysteinemia, which is an important confirmation of the significance of genetic factors in the body's susceptibility to various thromboembolic complications in MPD.
Keywords
Ph-negative myeloproliferative diseases, methylenetetrahydrofolate reductase, hyperhomocysteinemia, thromboembolism.
References
- Abdulkadyrov K. M., Shuvaev V. A., Martynkevich I. S. Modern approaches to the diagnosis and treatment of essential thrombocythemia: literature review and own data. Clinical oncohematology. Fundamental Research and Clinical Practice 2015;8(3): 235-47.
- Kerimov A. A. Chronic myeloproliferative diseases: current state of the issue, biomedicine 3/2014, pp. 3-8.
- Kozlovskaya M. A., Martynkevich I. S., Petrova E. V. Genetic diagnostics of Ph-negative chronic myeloproliferative diseases (CMP) / / Bulletin of Hematology. - 2013. - T. 9 No. 2. - p. 27.
- Melikyan A. L., Turkina A. G., Abdulkadyrov K. M. et al. Clinical guidelines for the diagnosis and treatment of Ph-negative myeloproliferative diseases (true polycythemia, essential thrombocythemia, primary myelofibrosis). II Congress of Hematologists (April 2014). Moscow, 2014.
- Melikyan A. L., Subortseva I. N., Sukhanova G. A. Thrombohemorrhagic complications in patients with Ph-negative myeloproliferative diseases. Blood. 2014; 2(18): 21–5.
- Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.
- Asp J., Andrew asson B., Hansson U..et al. Mutational status of essential thrombocythemia and primary myelofibrosis defines clinical outcomes. Haematologia 2016;101(4):e129-e132. DOI: 10.3324/haematol.2015.138958. PMID: 26768689.
- Beer, P A. How I treat essential thrombocythemia / P. A. Beer, W. N. Erber, P. J. Campbell, A. R. Green // Blood. — 2011. — Vol. 117 № 5. — P. 1472–1482.
- Falanga A, Marchetti R. Thrombosis in myeloproliferative neoplasms. Semin. Thromb. Hemost. 2014; 40 (3): 348–358.
- Fu R, Zhang L, Yang R. Pediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br. J. Haematol. 2013; 163: 295–302.
- Moulard O., Mehta J., Fryzek J. et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur. J. Haematol. 2014; 92: 289–97.
- Quintas-Cardama A., Abdel-Wahab O., Manshouri T. et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon 2a. Blood. 2013; 122(6): 893–901.
- Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(6):507–16.